WG
CATX icon

Winton Group’s Perspective Therapeutics CATX Stock Holding History

Winton Group’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,300
Closed -$101K – 1208
2026
Q1 		$101K Buy
+24,300
New +$103K ﹤0.01% 1040
2024
Q3 		– Sell
-84,363
Closed -$841K – 635
2024
Q2 		$841K Buy
+84,363
New +$1.22M 0.06% 357

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Winton Group's CATX Position: Q2 2026 in Review

Winton Group sold out of Perspective Therapeutics (CATX) in Q2 2026, closing a stake of 24,300 shares — an estimated $101K sold.

Winton Group first reported a position in CATX in Q2 2024 and held it in 2 quarters. The position peaked at $841K in Q2 2024. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Winton Group reported no remaining Perspective Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Winton Group sold 24,300 Perspective Therapeutics shares in Q2 2026, an estimated $101K.
  • Winton Group first reported a position in Perspective Therapeutics in Q2 2024 and held it in 2 quarters.
  • Winton Group's Perspective Therapeutics position peaked at $841K in Q2 2024.
  • 132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.